Clinical significance of SOX10 in breast carcinomas is not fully understood, but it is considered a useful marker [62];Approximately 66–74% of triple-negative breast carcinomas express SOX10 [63];Prognostic value is unclear, but there is evidence suggesting a possible contribution to malignant characteristics [62];High sensitivity in identifying triple-negative breast carcinomas [62,63,64]. This evidence concerns the gene SOX10 and triple-negative breast carcinoma.